BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) reported on Saturday, March 24th at the First Annual Symposium on Thymosins in Health and Disease, in Washington, D.C., new data relating to Thymosin beta 4’s (Tß4) effects in an ischemic cardiovascular animal model. Mr. David Crockford, RegeneRx’s vice president for clinical and regulatory affairs, reported that when Tß4 was administered intravenously to mice that had a surgically induced myocardial infarction (heart attack), approximately 73% survived for the duration of the study compared to 47% for those receiving placebo.
